TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03510611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib with fed or fasting
Description: The two groups of subjects were given an equal dose of Ensartinib capsules (225 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of Ensartinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib with fed or fasting
Description: The two groups of subjects were given an equal dose of Ensartinib capsules (225 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of Ensartinib.
Study: NCT04577014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)
Study: NCT03685942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active light therapy (LUMINETTE®)
Description: light therapy on a portable light visor device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo light therapy
Description: placebo portable light visor device
Study: NCT04577014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),
Study: NCT02037529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV
Study: NCT04577014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),
Study: NCT02037529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04577014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),
Study: NCT03676166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Inhaled cannabis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Inhaled cannabis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Inhaled cannabis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Inhaled cannabis
Study: NCT03866109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temferon
Description: Genetically modified HSPCs
Study: NCT02264639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor
Study: NCT02037529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02368197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel (Cardionovum Legflow drug eluting balloon)
Description: Elution of paclitaxel from inflated balloon catheter into vessel wall

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon angioplasty (Bard Dorado)
Description: Dilatation of cephalic arch venous stenosis by radial force applied by a balloon catheter
Study: NCT03295084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Dose Escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Dose Escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Dose Escalation
Study: NCT00913172

Intervention type: OTHER
Intervention: Treatment
Description: Directly observed treatment (DOT) by health extension workers (HEWs)
Study: NCT02520622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital photographs loaded onto a mobile device

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital photographs loaded onto a mobile device

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital photographs loaded onto a mobile device

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital photographs loaded onto a mobile device

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin exam reminders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin exam reminders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support network

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support network
Study: NCT03609528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamPROBE
Description: To be completed
Study: NCT00647530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT00664430

Intervention type: DRUG
Group type: OTHER
Intervention: Calcitriol
Description: Initial doses determined according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guideline (Am J Kidney Dis 2003;42(4)Suppl 3:S1-S201). During therapy, calcitriol dose may be modified by 0.5 - 1 mcg at 2- to 4-week intervals.

Intervention type: DRUG
Group type: OTHER
Intervention: Paricalcitol
Description: Dose calculated by 0.04 to 0.1 microgram per kilogram (mcg/kg). Paricalcitol will be administered intravenously after the participants' dialysis. The paricalcitol dose will be titrated every 2 weeks until iPTH presents a reduction or up to 4 months, after which it will be adjusted monthly based on serum PTH, calcium, phosphorus and albumin measurements. Dosing may be modified by 2-4 mcg increments at 2- to 4-week intervals.
Study: NCT03404583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred care at distance through an eHealth platform
Description: Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
Study: NCT05437783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Dihydrate
Description: exclusively hospitalized at Bandarban Sadar hospital, Bandarban, Bangladesh. Participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Dihydrate
Description: exclusively hospitalized at Bandarban Sadar hospital, Bandarban, Bangladesh. Participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
Study: NCT02876770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Melatonin
Description: Our protocol was composed of three experimental sessions. During each testing session, participants were requested to attend the laboratory at 20:00h where they ingested a standardized light meal. Melatonin (5 mg or 8 mg) or placebo were ingested in capsule in the evening at 21:00h in a double-blind randomized design

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In a double-blind randomized design, participants have taken placebo supplementation in one of the three experimental sessions
Study: NCT02042729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022- Current Formula Tape
Description: Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2022- New Formula Tape
Description: Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E2022 Matching Placebo- Current Formula Tape
Study: NCT03549520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride lipid-type A microspheres
Description: Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg.
Study: NCT02042729

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E2022 Matching Placebo- New Formula Tape
Study: NCT03959839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESD
Description: Rectal Endoscopic Submucosal Dissection
Study: NCT02238496

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cytoreductive surgery
Description: Standard of care/routine cytoreductive glioma resection surgery. Arm B only.

Intervention type: DRUG
Group type: OTHER
Intervention: Perifosine
Description: Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.
Study: NCT03192436

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Low-intensity (Ispta \< 720 mW/cm2, Isppa \< 190 W/cm2) transcranial focused ultrasound
Study: NCT03959839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAMIS
Description: Transanal Minimally Invasive Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEO
Description: Transanal Endoscopic Operation
Study: NCT02238496

Intervention type: DRUG
Group type: OTHER
Intervention: Perifosine
Description: Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.

Intervention type: DRUG
Group type: OTHER
Intervention: Temsirolimus
Description: Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.

Intervention type: DRUG
Group type: OTHER
Intervention: Temsirolimus
Description: Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.
Study: NCT04474899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.4 MG
Description: Participants will be randomly assigned to receive moxonidine 0.4mg/daily and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.4 MG
Description: Participants will be randomly assigned to receive moxonidine 0.4mg/daily and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Participants will be randomly assigned to receive amlodipine 5mg and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Participants will be randomly assigned to receive amlodipine 5mg and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
Study: NCT01341652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP
Description: pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rhGM-CSF
Description: rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
Study: NCT03192436

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound
Description: Low-intensity (Ispta \< 720 mW/cm2, Isppa \< 190 W/cm2) transcranial focused ultrasound
Study: NCT01889914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 different procedures of administration of insulin
Description: Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 different procedures of administration of insulin
Description: Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump
Study: NCT03624725

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified BII+Braun
Description: modified BII+Braun digestive tract reconstruction
Study: NCT00966108

Intervention type: DEVICE
Intervention: SENSIMED Triggerfish
Description: Ocular Telemetry Sensor for IOP monitoring

Intervention type: DEVICE
Intervention: SENSIMED Triggerfish
Description: Ocular Telemetry Sensor for IOP monitoring
Study: NCT00806585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-0736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: HCTZ
Study: NCT01103414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoglitazone
Description: 50 mg capsules, once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoglitazone
Description: Mitoglitazone 100 mg capsules, once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoglitazone
Description: Mitoglitazone 150 mg capsules, once daily for 84 days
Study: NCT00115804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine po 10-60 mg/day for 12 weeks. Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily
Study: NCT04129606

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Computed tomographic cystography
Description: CT cystogram performed after the procedure by the injection of 400mL of 1/4 saline-diluted contrast solution (meglumine ioxitalamate) with low-pressure infusion (60 cm gravity pressure) through the Foley catheter.
Study: NCT03766334

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Highland Barley Diet
Description: Highland Barley Diet(20g, thrice-daily)
Study: NCT01103414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 45 mg, once daily for 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily for 84 days
Study: NCT02297334

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb device
Description: In 20 patients the CytoSorb device will be installed into the extra corporeal circuit. A blood flow of 400ml/min is provided by an roller pump of the heart lung machine in a parallel stream to the main circulation.
Study: NCT04103255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High frequency and intensive prevention program
Description: This study is a 4 week non-randomized controlled trial (RCT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High frequency and intensive prevention program
Description: This study is a 4 week non-randomized controlled trial (RCT)
Study: NCT04209647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REHIT Exercise
Description: -Start with warm-up period --\> %50 of maximum work rate, 3 minutes~One Exercise Cycle consists of:~* 15 seconds exercise period: %100 of maximum work rate~* 15 seconds recovery period: %50 of maximum work rate~Total Duration: 10 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Aerobic Exercise
Description: At %50 of maximum heart rate, 30-60 minutes aerobic exercise
Study: NCT00233259

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: Mediterranean dietary program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Physical activity program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: Stress management program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Support
Description: Social support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: Smoking cessation program
Study: NCT00637910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg/day per os until disease progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/mq on day 1, every 21 days (3-weekly schedule) or Docetaxel 35 mg/mq 0n day 1,8 and 15 every 28 days (weekly schedule). _Until disease progression or unacceptable toxicity develops
Study: NCT02825108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra uterine injection of tissue culture medium containing HCG+ET
Description: 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.